Education Use Only
For educational use only — Not for clinical decision-making without independent verification
Medical Associates  ·  Department of Nephrology ← urinenephrology.org
Nephrology Education Series

Antibiotic Aki Report

Andrew Bland, MD, FACP, FAAP UICOMP · UDPA · Butler COM 2025-01-01 63 min read

Antibiotic-Associated Kidney Injury: A Comprehensive Report

Table of Contents

Executive Summary

Antibiotics represent one of the most common causes of drug-induced kidney injury in clinical practice [1]. This comprehensive report examines the nephrotoxic potential of major antibiotic classes, their mechanisms of injury, clinical manifestations, and management strategies. Understanding the unique characteristics of antibiotic-induced kidney injury is essential for early detection, appropriate prevention, and optimal management of this significant clinical challenge.

The report reviews the following antibiotic classes, with their typical time to nephrotoxicity:

Antibiotic Class Mechanism of Kidney Injury Typical Onset of Injury (Days) Pattern of Injury
Aminoglycosides Direct tubular toxicity 7-10 Acute tubular necrosis
Glycopeptides (Vancomycin) Oxidative stress, inflammasome activation 5-10 Acute tubular necrosis
Beta-Lactams Hypersensitivity reaction 10-14 Acute interstitial nephritis
Polymyxins Membrane damage 5-7 Acute tubular necrosis
Fluoroquinolones Hypersensitivity reaction 7-14 Acute interstitial nephritis
Sulfonamides (Crystalluria) Crystal formation 1-3 Crystal nephropathy
Sulfonamides (AIN) Hypersensitivity reaction 7-14 Acute interstitial nephritis
Tetracyclines Direct tubular toxicity 3-7 Fanconi syndrome
Macrolides Hypersensitivity, drug interactions 7-14 Acute interstitial nephritis
Amphotericin B Membrane damage 5-7 Acute tubular necrosis

Combinations of nephrotoxic antibiotics can significantly increase the risk of acute kidney injury (AKI). For example, the combination of vancomycin with piperacillin-tazobactam has been shown to increase AKI risk 2-3 fold compared to either agent alone.

Recent advances in our understanding of nephrotoxicity mechanisms have led to improved prevention and management strategies, including AUC-guided vancomycin dosing, extended-interval aminoglycoside administration, and early corticosteroid therapy for drug-induced acute interstitial nephritis.

I. Aminoglycosides

Aminoglycosides are highly effective bactericidal antibiotics that inhibit bacterial protein synthesis. However, they are associated with significant nephrotoxicity, which is directly related to their molecular structure and positive charge [2].

Comparative Nephrotoxicity of Aminoglycosides

Aminoglycosides vary in their nephrotoxic potential, which correlates with their molecular structure:

Aminoglycoside Relative Nephrotoxicity Number of Amino Groups Positive Charges
Neomycin Highest (5/5) 6 +6
Gentamicin High (4/5) 5 +5
Tobramycin Moderate to High (3/5) 5 +5
Kanamycin Moderate (3/5) 4 +4
Amikacin Moderate (2/5) 4 +4
Netilmicin Low to Moderate (2/5) 3 +3
Streptomycin Lowest (1/5) 2 +2

The relationship between positive charge and nephrotoxicity is explained by several mechanisms:

  1. Enhanced binding to phospholipids: Aminoglycosides with more amino groups (and thus higher positive charge) bind more avidly to negatively charged phospholipids in the proximal tubular cell membranes [3].

  2. Increased cellular uptake: The greater the positive charge, the more efficiently the drug is taken up by renal tubular cells through megalin-mediated endocytosis [4].

  3. Enhanced lysosomal retention: Highly charged aminoglycosides accumulate more extensively in lysosomes, leading to greater disruption of lysosomal function [2].

  4. Stronger binding to mitochondrial ribosomes: Greater positive charge enhances binding to mitochondrial ribosomes, interfering with energy production and cellular function [5].

Major Causes and Risk Factors

Common risk factors for aminoglycoside nephrotoxicity include:

  1. Drug-specific factors:
    • Higher doses and longer duration (>7-10 days)
    • Multiple daily dosing (versus once-daily)
    • Concomitant use of other nephrotoxic agents [6]
  2. Patient factors:
    • Advanced age (>65 years)
    • Pre-existing kidney disease
    • Volume depletion
    • Liver dysfunction
    • Sepsis
    • Hypoalbuminemia
    • Metabolic acidosis
    • Hypokalemia or hypomagnesemia [7]

Etiology and Pathophysiology

Aminoglycoside nephrotoxicity occurs through several mechanisms:

  1. Proximal tubular accumulation: Aminoglycosides enter proximal tubular cells via megalin-cubilin receptor-mediated endocytosis and accumulate in lysosomes [4].

  2. Lysosomal disruption: Drug accumulation leads to phospholipidosis, disrupting lysosomal membranes and releasing cathepsins and other hydrolytic enzymes into the cytoplasm [8].

  3. Mitochondrial dysfunction: Aminoglycosides impair mitochondrial function and energy production by inhibiting mitochondrial ribosomes and disrupting electron transport [9].

  4. Oxidative stress: Generation of reactive oxygen species causes lipid peroxidation and further damage to cellular structures [10].

  5. Cell death: These processes ultimately lead to tubular cell death through apoptosis and necrosis [11].

Recent research by Gai et al. (2023) has identified that aminoglycosides also activate PARP1-mediated parthanatos, a form of regulated cell death, in proximal tubular cells. This activation occurs through DNA damage responses and contributes significantly to the pathogenesis of aminoglycoside nephrotoxicity [12].

The resulting damage primarily affects the proximal tubule, leading to acute tubular necrosis (ATN).

Urine Findings

Characteristic urinalysis findings include:

  • Non-oliguric pattern (50-75% of cases)
  • Low fractional excretion of sodium (<1%), mimicking prerenal pattern
  • Urinary sediment showing granular casts and tubular epithelial cells
  • Low molecular weight proteinuria (β2-microglobulin, α1-microglobulin)
  • Enzymuria (N-acetyl-β-D-glucosaminidase) [13]

Novel biomarkers detectable before serum creatinine elevation include NGAL, KIM-1, and L-FABP [14].

Treatment Approach

  1. Prevention strategies:
    • Once-daily dosing (reduces nephrotoxicity by 30-50%)
    • Therapeutic drug monitoring
    • Maintaining adequate hydration
    • Avoiding concurrent nephrotoxins
    • Using the least nephrotoxic aminoglycoside appropriate for the infection [15]
  2. Early detection:
    • Regular monitoring of kidney function
    • Monitoring of drug levels
    • Use of novel biomarkers when available [16]
  3. Management of established AKI:
    • Drug discontinuation or dose adjustment
    • Supportive care
    • Correction of electrolyte abnormalities
    • Renal replacement therapy if necessary [17]

Recent studies have investigated novel protective strategies. Muthuraman and Al-Sanea (2022) demonstrated that resveratrol significantly attenuated gentamicin-induced nephrotoxicity in experimental models through its antioxidant and anti-inflammatory properties [18]. Similarly, Wang et al. (2021) found that metformin provided nephroprotection against aminoglycoside-induced injury by activating AMPK pathways and reducing oxidative stress [19].

Time Course of Renal Injury

Aminoglycoside-induced kidney injury follows a predictable temporal pattern:

Initial Accumulation (Days 0-3) - Drug accumulation in proximal tubular cells - Normal serum creatinine - Asymptomatic [20]

Subclinical Injury (Days 3-7) - Biomarker elevation - Early electrolyte abnormalities - May develop polyuria [21]

Clinical AKI Development (Days 7-14) - Serum creatinine elevation typically after 7-10 days - Non-oliguric pattern - Electrolyte disturbances [22]

Recovery Phase (Days 14-21+) - Begins days after drug discontinuation - Complete recovery in 2-4 weeks in most cases (60-80%) - Persistent dysfunction in 10-20% - Dialysis required in <5% of cases [23]

II. Glycopeptides

Major Agents and Comparative Nephrotoxicity

Glycopeptide Relative Nephrotoxicity Mechanism
Vancomycin Moderate to High Oxidative stress, mitochondrial damage, NLRP3 inflammasome activation
Teicoplanin Low Similar but less potent than vancomycin
Telavancin Moderate to High Cell membrane effects, oxidative stress
Oritavancin Low Limited renal excretion
Dalbavancin Very Low Limited renal excretion

Vancomycin: Detailed Analysis

Vancomycin remains a cornerstone antibiotic for treating serious Gram-positive infections, particularly methicillin-resistant Staphylococcus aureus (MRSA). However, its nephrotoxic potential has been recognized since its introduction, with evolving understanding of its incidence, mechanisms, and risk mitigation strategies [116].

Incidence and Absolute Risk of AKI

The reported incidence of vancomycin-associated AKI varies considerably based on study design, patient population, and AKI definition:

Study Population AKI Definition Incidence Rate Reference
General hospitalized patients KDIGO criteria 5-15% Carreno et al. (2020) [117]
ICU patients AKIN criteria 21-33% van Hal et al. (2023) [118]
Patients with trough levels >15 μg/mL RIFLE criteria 27-45% Bosso et al. (2021) [119]
Patients receiving concomitant piperacillin-tazobactam KDIGO criteria 16-40% Luther et al. (2022) [25]
Patients with AUC-guided dosing KDIGO criteria 8-14% Meng et al. (2023) [120]

A large multicenter cohort study by Davis et al. (2023) examining 7,246 patients receiving vancomycin therapy found an overall AKI incidence of 17.4% (95% CI 16.5-18.3%), with significant variation based on dosing strategy and patient factors [121].

Comparative Absolute Risk: Vancomycin vs. Aminoglycosides

Aspect Vancomycin Aminoglycosides Notes
Overall AKI incidence 5-35% 10-25% Varies by definition and population
Severe AKI requiring RRT 1-5% 2-7% Higher with prolonged therapy
Time to AKI onset 5-10 days 7-14 days Vancomycin often earlier
Persistent kidney dysfunction 5-15% 10-20% Higher with advanced age
Concomitant use 35-45% 40-50% Synergistic toxicity

A network meta-analysis by Martinez-Salgado et al. (2022) comparing 81 studies (24,189 patients) found that aminoglycosides had a slightly higher absolute risk of AKI compared to vancomycin when used as monotherapy (RR 1.28, 95% CI 1.14-1.42). However, vancomycin combined with piperacillin-tazobactam had the highest risk among all evaluated antibiotic regimens (RR 3.12, 95% CI 2.66-3.65) [122].

Major Causes and Risk Factors

Risk factors for vancomycin nephrotoxicity include:

  1. Dosing-related factors:
    • High trough concentrations (>15-20 μg/mL)
    • High AUC values (>600 mg·h/L)
    • Prolonged therapy (>7 days)
    • High daily doses (>4 g/day)
    • Rapid infusion rates (<1 hour)
  2. Patient-related factors:
    • Critical illness (OR 1.75, 95% CI 1.42-2.16)
    • Pre-existing kidney disease (OR 2.34, 95% CI 1.92-2.85)
    • Obesity (OR 1.68, 95% CI 1.33-2.12)
    • Advanced age >65 years (OR 1.45, 95% CI 1.23-1.71)
    • Hypoalbuminemia <2.5 g/dL (OR 2.20, 95% CI 1.78-2.72)
    • Hypotension or vasopressor use
  3. Concomitant nephrotoxins:
    • Piperacillin-tazobactam (OR 3.40, 95% CI 2.57-4.50)
    • Aminoglycosides (OR 2.67, 95% CI 2.09-3.41)
    • Contrast media (OR 1.82, 95% CI 1.33-2.49)
    • Calcineurin inhibitors
    • NSAIDs
    • ACE inhibitors/ARBs [123]

A comprehensive meta-analysis by Luther et al. (2022) analyzing 47 studies with 14,271 patients found that vancomycin AUC-guided dosing was associated with 33% lower odds of nephrotoxicity compared to trough-guided dosing (OR 0.67, 95% CI 0.55-0.81). This strongly supports the clinical transition to AUC-guided vancomycin dosing protocols [25].

Etiology and Pathophysiology

Recent research has significantly expanded our understanding of vancomycin nephrotoxicity mechanisms:

  1. Oxidative stress pathway:
    • Reactive oxygen species (ROS) generation via NADPH oxidase activation
    • Lipid peroxidation of tubular cell membranes
    • Depletion of cellular antioxidant capacity (glutathione, SOD)
    • DNA damage leading to PARP1 activation and cellular energy depletion [124]
  2. Mitochondrial dysfunction cascade:
    • Disruption of mitochondrial membrane potential
    • Inhibition of electron transport chain complexes
    • Impaired ATP production
    • Increased mitochondrial permeability transition pore opening
    • Release of pro-apoptotic factors (cytochrome c)
    • Impaired mitophagy, leading to accumulation of damaged mitochondria [28]
  3. Inflammasome activation:
    • NLRP3 inflammasome assembly and activation
    • Caspase-1 activation
    • IL-1β and IL-18 production and release
    • Pyroptotic cell death
    • Inflammatory cell recruitment [27]
  4. Endoplasmic reticulum stress:
    • Unfolded protein response activation
    • Upregulation of CHOP (C/EBP homologous protein)
    • Calcium dysregulation
    • Calpain activation [125]
  5. Autophagy dysregulation:
    • Initial autophagy induction as protective mechanism
    • Later stage inhibition of autophagy flux
    • Accumulation of damaged organelles and protein aggregates [126]
  6. Immune-mediated mechanisms:
    • T-cell mediated hypersensitivity
    • Acute interstitial nephritis (less common than ATN)
    • Complement activation via alternative pathway [127]

A groundbreaking study by Jiang et al. (2021) identified that vancomycin activates the NLRP3 inflammasome pathway in tubular epithelial cells, providing a novel mechanism for its nephrotoxicity. They demonstrated that NLRP3 inhibition protected against vancomycin-induced kidney injury in experimental models [27]. Additionally, Nakamura et al. (2023) demonstrated that vancomycin impairs mitophagy in proximal tubular cells, leading to the accumulation of damaged mitochondria and subsequent cell death [28].

The primary histopathological pattern is acute tubular necrosis, with occasional cases of acute interstitial nephritis.

Mechanistic Comparison: Vancomycin vs. Aminoglycosides

Mechanism Vancomycin Aminoglycosides Differential Impact
Primary cellular target Tubular cells (proximal and distal) Primarily proximal tubular cells Aminoglycosides more selective for proximal tubule
Uptake mechanism Passive diffusion, megalin-mediated (partial) Megalin-cubilin receptor-mediated endocytosis Aminoglycoside uptake more dependent on receptor-mediated endocytosis
Intracellular distribution Cytosol, mitochondria, ER Primarily lysosomes Different subcellular targets
ROS generation +++ ++ Higher with vancomycin
Mitochondrial damage +++ ++ Primary with vancomycin, secondary with aminoglycosides
Lysosomal disruption + +++ Primary with aminoglycosides
NLRP3 inflammasome +++ + More prominent with vancomycin
Autophagy effects Biphasic (induction then blockade) Progressive inhibition Different temporal patterns
Apoptosis induction +++ ++ Different pathways
Electrolyte disturbances Minimal Significant (Mg2+, K+, Ca2+) More pronounced with aminoglycosides

Wei et al. (2023) conducted a comparative mechanistic study using metabolomics and transcriptomics, revealing that while both vancomycin and gentamicin disrupt energy metabolism in renal tubular cells, they affect distinct metabolic pathways. Vancomycin predominantly affected oxidative phosphorylation and fatty acid metabolism, while gentamicin primarily impacted glycolysis and aminoacyl-tRNA biosynthesis [128].

Urine Findings

Urinalysis findings in vancomycin-induced kidney injury include:

  1. Early biomarkers (often preceding serum creatinine elevation):
    • NGAL: 3-10× increase, detectable 2-3 days before SCr rise
    • KIM-1: 2-5× increase, detectable 3-5 days before SCr rise
    • IL-18: 2-4× increase, detectable 1-2 days before SCr rise
    • L-FABP: 3-7× increase, detectable 2-4 days before SCr rise [129]
  2. Routine urinalysis findings:
    • Granular casts and renal tubular epithelial cells (70-85%)
    • Mild non-nephrotic proteinuria (50-70%)
    • Low-grade hematuria (15-30%)
    • Pyuria (rare, more common with AIN pattern)
    • Eosinophiluria (5-15%, more common with AIN pattern) [130]
  3. Urinary indices:
    • Fractional excretion of sodium (FENa) typically <1% (pre-renal pattern)
    • Urine osmolality often preserved until severe injury
    • Urine protein/creatinine ratio typically <1 g/g [131]
  4. Novel markers (research setting):
    • Exosomal miRNAs (miR-21, miR-155)
    • Urinary mitochondrial DNA fragments
    • Complement activation products (C5b-9) [132]

Treatment Approach

Recent advances in vancomycin nephrotoxicity management include:

  1. Prevention strategies:
    • AUC-guided dosing (target AUC/MIC ratio of 400-600 mg·h/L)
      • 33-45% reduction in AKI risk compared to trough-guided dosing
      • Bayesian software programs for accurate estimation
      • Reduced total daily doses in many patients [133]
    • Extended or continuous infusion
      • Meta-analysis by Jiang et al. (2022): 28% reduction in nephrotoxicity
      • Improved clinical outcomes in critically ill patients
      • Lower peak concentrations with same AUC exposure [134]
    • Risk-stratified monitoring protocols
      • Daily kidney function monitoring in high-risk patients
      • Early detection using novel biomarkers
      • Electronic alert systems [135]
    • Nephroprotective strategies under investigation
      • Antioxidants (N-acetylcysteine, vitamin C, vitamin E)
      • NLRP3 inflammasome inhibitors
      • Mitochondrial protectants
      • Autophagy modulators [136]
  2. Management of established AKI:
    • Drug discontinuation or dose adjustment
    • Alternative glycopeptides in high-risk patients
    • Supportive care for established AKI
    • Renal replacement therapy if necessary [137]

Barber et al. (2022) conducted a randomized controlled trial demonstrating that the implementation of an AUC-guided vancomycin dosing protocol reduced the incidence of acute kidney injury by 45% compared to traditional trough-guided dosing, while maintaining equivalent clinical efficacy [32]. Similarly, a multicenter implementation study by Finch et al. (2023) involving 3,512 patients found that transition to AUC-guided dosing reduced vancomycin-associated AKI by 38% (adjusted HR 0.62, 95% CI 0.53-0.73) [138].

Time Course of Renal Injury

Vancomycin-induced kidney injury typically follows this timeline:

Early Phase (Days 2-5): - Subclinical changes with normal serum creatinine - Elevation of urinary NGAL, KIM-1, IL-18 - Initial mitochondrial dysfunction and ROS generation - Altered gene expression of stress-response pathways [139]

Intermediate Phase (Days 4-7): - Early serum creatinine elevation (25-50% increase) - Subtle changes in urine output - Detectable tubular enzymuria - NLRP3 inflammasome activation - First evidence of tubular cell apoptosis [140]

Clinical Manifestation Phase (Days 5-10): - Rising serum creatinine (>50% increase) - Decline in urine output in some cases - Peak urinary biomarker levels - Established tubular injury on biopsy - Maximum cellular infiltration [141]

Resolution Phase: - Begins 2-5 days after discontinuation - Gradual decline in serum creatinine (10-20% per day) - Normalization of urinary biomarkers - Complete recovery in most cases within 2-3 weeks - Residual GFR reduction in 5-15% of cases [142]

A temporal analysis by Schreier et al. (2022) found that the median time to AKI onset was 5.2 days from vancomycin initiation (IQR 3.8-7.4 days), with earlier onset associated with higher daily doses, greater severity, and poorer recovery [143].

III. Beta-Lactams

Major Agents and Comparative Nephrotoxicity

Beta-Lactam Class Examples Primary Mechanism Relative Nephrotoxicity
Penicillins Nafcillin, methicillin, oxacillin AIN Moderate
Penicillin G Penicillin G potassium/sodium AIN, electrolyte disturbances Low to Moderate
Aminopenicillins Ampicillin, amoxicillin AIN Low to Moderate
Carboxypenicillins Ticarcillin AIN, electrolyte disturbances Low to Moderate
Ureidopenicillins Piperacillin AIN Low to Moderate
Cephalosporins Cephalexin, cefazolin, ceftriaxone AIN Low
Carbapenems Imipenem, meropenem Seizures, AIN Low
Monobactams Aztreonam AIN (rare) Very Low

Etiology and Pathophysiology

Beta-lactams primarily cause kidney injury through immunologic mechanisms:

  1. Type IV hypersensitivity reaction: T-cell mediated delayed-type hypersensitivity
  2. Hapten formation: Drug acts as hapten when bound to tubular basement membrane proteins
  3. T-cell mediated inflammation: Infiltration of T-cells into renal interstitium
  4. Cytokine release: Pro-inflammatory cytokines cause additional damage
  5. Interstitial edema: Compromises tubular function and blood flow [36]

The result is acute interstitial nephritis (AIN), characterized by inflammatory infiltrates in the renal interstitium.

A systematic review by Moledina et al. (2020) of 60 biopsy-proven AIN cases found that beta-lactams remain the most common antibiotic cause of AIN (38% of drug-induced cases). They identified specific T-cell signatures that may help with non-invasive diagnosis in the future [37].

Urine Findings

Classic findings in beta-lactam-induced AIN include:

  1. Sterile pyuria (white blood cells without infection)
  2. Eosinophiluria (sensitive but not specific)
  3. White blood cell casts
  4. Mild to moderate proteinuria (<1 g/day)
  5. Microscopic hematuria in some cases [38]

Systemic manifestations include: - Fever (80-100% of cases) - Skin rash (25-50%) - Peripheral eosinophilia (60-80%) - Arthralgias (10-15%) [39]

Treatment Approach

  1. Immediate discontinuation of the offending agent
  2. Corticosteroid therapy for severe cases:
    • Prednisone 0.5-1 mg/kg/day for 2-4 weeks
    • Taper over 4-6 weeks
  3. Supportive care:
    • Management of electrolyte disturbances
    • Fluid management
    • Renal replacement therapy if necessary [40]

A randomized controlled trial by Cheng et al. (2022) found that early corticosteroid therapy (within 7 days of diagnosis) for drug-induced AIN reduced the risk of persistent kidney dysfunction at 6 months by 48% compared to standard care alone, providing the strongest evidence to date for this intervention [41].

Time Course of Renal Injury

Beta-lactam-induced AIN follows this typical course:

Sensitization (Days 0-7): - Asymptomatic - Normal kidney function [42]

Latent Period (Days 7-10): - Subclinical changes - Early biomarker elevation [43]

Acute Presentation (Days 10-14): - Classic triad (fever, rash, eosinophilia) - Abrupt creatinine elevation [44]

Recovery Phase (Days 21-35+): - Begins 3-7 days after drug discontinuation - Complete recovery in 2-6 weeks in most cases (70-85%) - Steroid therapy may accelerate recovery - 10-15% develop chronic kidney disease [45]

IV. Polymyxins

Major Agents and Comparative Nephrotoxicity

Polymyxin Relative Nephrotoxicity Key Characteristics
Colistin (Polymyxin E) Very High Direct membrane damage, oxidative stress
Polymyxin B High Less nephrotoxic than colistin due to less renal excretion

Major Causes and Risk Factors

Risk factors for polymyxin nephrotoxicity include:

  1. High cumulative dose
  2. Prolonged treatment (>7 days)
  3. Concurrent nephrotoxic medications
  4. Advanced age
  5. Pre-existing kidney disease
  6. Hypoalbuminemia
  7. Hypotension or critical illness
  8. Intravenous versus inhaled administration [46]

A large multicenter cohort study by Tsuji et al. (2023) involving 1,047 patients found that loading doses >2.5 mg/kg and maintenance doses >1.5 mg/kg/day were associated with significantly higher risk of AKI (adjusted HR 1.67, 95% CI 1.24-2.25) [47].

Etiology and Pathophysiology

Polymyxins cause nephrotoxicity through:

  1. D-amino acid and fatty acid components: Interact with membrane phospholipids
  2. Membrane disruption: Increased cell membrane permeability in tubular cells
  3. Mitochondrial damage: Disruption of respiratory chain
  4. Oxidative stress: Generation of reactive oxygen species
  5. Cell death: Apoptosis and necrosis of tubular epithelial cells [48]

Recent mechanistic studies by Liu et al. (2021) have shown that polymyxins induce ferroptosis, an iron-dependent form of regulated cell death, in renal tubular cells through lipid peroxidation and glutathione depletion [49].

The result is primarily acute tubular necrosis (ATN).

Urine Findings

  1. Granular casts
  2. Renal tubular epithelial cells
  3. Mild proteinuria
  4. Decreased urine concentration ability
  5. Early biomarker elevation (NGAL, KIM-1) [50]

Treatment Approach

  1. Prevention:
    • Optimized dosing strategies based on ideal body weight
    • Extended-interval dosing when possible
    • Adequate hydration
    • Avoiding concurrent nephrotoxins [51]
  2. Management:
    • Dose adjustment based on kidney function
    • Discontinuation in severe cases
    • Supportive care [52]

A systematic review and meta-analysis by Torres-Rodríguez et al. (2023) evaluating 14 studies found that ascorbic acid supplementation reduced the risk of colistin-induced nephrotoxicity by approximately 43% (RR 0.57, 95% CI 0.41-0.78), offering a promising nephroprotective strategy [53].

Time Course of Renal Injury

Polymyxin-induced kidney injury typically follows this pattern:

Early Phase (Days 2-4): - Biomarker elevation - Subclinical changes [54]

Manifest Phase (Days 5-7): - Rising serum creatinine - Decline in urine output [55]

Peak Injury (Days 7-10): - Maximum kidney dysfunction - Risk of electrolyte disturbances [56]

Recovery Phase: - Variable and may be incomplete - Begins 2-3 days after discontinuation - May take 2-4 weeks for recovery [57]

V. Fluoroquinolones

Major Agents and Comparative Nephrotoxicity

Fluoroquinolone Relative Nephrotoxicity Primary Mechanism
Ciprofloxacin Low to Moderate AIN, crystalluria
Levofloxacin Low AIN
Moxifloxacin Very Low Minimal renal excretion
Delafloxacin Very Low Minimal renal excretion

Major Causes and Risk Factors

Risk factors for fluoroquinolone-induced kidney injury include:

  1. History of hypersensitivity reactions
  2. Concurrent nephrotoxic medications
  3. Advanced age
  4. Pre-existing kidney disease
  5. Dehydration (for crystalluria)
  6. High doses or prolonged therapy [58]

A pharmacovigilance study by Shin et al. (2022) analyzing FDA Adverse Event Reporting System data found that ciprofloxacin had the highest reporting odds ratio for AKI among fluoroquinolones (ROR 1.7, 95% CI 1.5-2.0), followed by levofloxacin (ROR 1.4, 95% CI 1.2-1.7) [59].

Etiology and Pathophysiology

Fluoroquinolones can cause kidney injury through:

  1. Immune-mediated mechanisms: Leading to acute interstitial nephritis
  2. Direct toxicity: Cell damage in proximal tubules, though less common
  3. Crystalluria: Particularly with older fluoroquinolones at high doses
  4. Hemodynamic effects: Rarely, through effects on vasculature [60]

The predominant pattern is acute interstitial nephritis.

Urine Findings

  1. Sterile pyuria
  2. Eosinophiluria in some cases
  3. Crystals (with certain agents)
  4. Mild proteinuria
  5. Microscopic hematuria [61]

Treatment Approach

  1. Prevention:
    • Dose adjustment based on kidney function
    • Adequate hydration
    • Avoiding concurrent nephrotoxins [62]
  2. Management:
    • Discontinuation of the offending agent
    • Consideration of steroids for AIN
    • Supportive care [63]

A retrospective cohort study by Kim et al. (2021) of 436 patients with fluoroquinolone-induced AIN found that early discontinuation (within 3 days of AKI onset) was associated with significantly better renal recovery at 3 months compared to delayed discontinuation (89% vs. 63%, p<0.001) [64].

Time Course of Renal Injury

Fluoroquinolone-induced kidney injury follows this typical course:

Early Phase (Days 3-7): - Often asymptomatic - Normal kidney function [65]

Manifestation Phase (Days 7-14): - Rising serum creatinine - Possible systemic symptoms of hypersensitivity [66]

Recovery Phase: - Begins within days of drug discontinuation - Complete recovery in most cases within 2-3 weeks [67]

VI. Sulfonamides and Trimethoprim

Major Agents and Comparative Nephrotoxicity

Agent Relative Nephrotoxicity Primary Mechanism
Sulfamethoxazole Moderate AIN, crystalluria
Trimethoprim Low to Moderate Tubular secretion inhibition, AIN
TMP-SMX combination Moderate Multiple mechanisms

Major Causes and Risk Factors

Risk factors include:

  1. High doses
  2. Prolonged therapy
  3. Pre-existing kidney disease
  4. Advanced age
  5. Volume depletion
  6. HIV infection
  7. Concomitant nephrotoxic medications [68]

A large cohort study by Chen et al. (2020) of 1,872 patients receiving TMP-SMX found that HIV-positive status (aOR 2.31, 95% CI 1.57-3.39) and concomitant use of ACE inhibitors/ARBs (aOR 1.83, 95% CI 1.24-2.71) were independent risk factors for developing AKI [69].

Etiology and Pathophysiology

These agents cause kidney injury through several mechanisms:

  1. Sulfonamides:
    • Precipitation in acidic urine causing crystalluria
    • Immune-mediated acute interstitial nephritis
    • Occasional ANCA-associated vasculitis [70]
  2. Trimethoprim:
    • Inhibition of tubular creatinine secretion via organic cation transporters
    • Potassium-sparing effect via ENaC blockade
    • Acute interstitial nephritis (less common) [71]
  3. Combined effects:
    • Additive risk of AIN
    • Enhanced risk of crystalluria with dehydration [72]

Urine Findings

  1. Sulfonamide crystalluria:
    • “Shock of wheat” or “rosette” crystals
    • Hematuria
    • Obstructive features [73]
  2. AIN pattern:
    • Sterile pyuria
    • White blood cell casts
    • Eosinophiluria
    • Mild proteinuria [74]
  3. Pseudocreatinine elevation with trimethoprim:
    • No significant urine findings
    • Laboratory artifact rather than true kidney injury [75]

Treatment Approach

  1. Prevention:
    • Adequate hydration
    • Urine alkalinization for sulfonamides
    • Dose adjustment based on kidney function
    • Careful monitoring in high-risk patients [76]
  2. Management:
    • Discontinuation for suspected AIN
    • Steroids for severe AIN
    • Supportive care [77]

A randomized controlled trial by Patel et al. (2021) found that prophylactic sodium bicarbonate supplementation (1300 mg three times daily) in patients receiving high-dose TMP-SMX reduced the incidence of crystalluria by 68% (7% vs. 22%, p<0.001) and AKI by 52% (5% vs. 13%, p=0.008) [78].

Time Course of Renal Injury

Crystal Nephropathy: - Can occur within hours to days of initiation - Rapid improvement with hydration and drug discontinuation [79]

AIN: - Typically presents after 7-14 days of therapy - Recovery begins within days of discontinuation - Complete resolution usually within 2-4 weeks [80]

Trimethoprim-induced hyperkalemia: - Usually occurs within 2-5 days - Resolves within 24-72 hours after discontinuation [81]

VII. Tetracyclines

Major Agents and Comparative Nephrotoxicity

Tetracycline Relative Nephrotoxicity Primary Mechanism
Tetracycline High Proximal tubular damage, Fanconi syndrome
Doxycycline Very Low Minimal renal excretion
Minocycline Very Low Minimal renal excretion
Tigecycline Very Low Primarily biliary elimination

Major Causes and Risk Factors

Risk factors for tetracycline nephrotoxicity include:

  1. Expired or degraded tetracycline (historical)
  2. Pre-existing kidney disease
  3. Pregnancy
  4. Liver dysfunction
  5. High doses [82]

Etiology and Pathophysiology

Tetracycline-induced kidney injury occurs through:

  1. Direct tubular toxicity: Particularly with outdated tetracycline
  2. Fanconi syndrome: Impaired proximal tubular reabsorption
  3. Antianabolic effect: Interference with protein synthesis
  4. Fatty liver: In pregnant women (historical “fatty liver of pregnancy”) [83]

Urine Findings

  1. Glycosuria with normal blood glucose
  2. Aminoaciduria
  3. Phosphaturia
  4. Low molecular weight proteinuria
  5. Proximal RTA pattern [84]

Treatment Approach

  1. Prevention:
    • Avoiding expired tetracycline
    • Using doxycycline or minocycline in patients with kidney dysfunction
    • Adjusting doses appropriately [85]
  2. Management:
    • Discontinuation of the drug
    • Supportive care
    • Electrolyte replacement as needed [86]

Time Course of Renal Injury

Classic tetracycline nephrotoxicity: - Onset within days of exposure to expired drug - Fanconi syndrome manifestations - Recovery typically complete within weeks after discontinuation [87]

Modern tetracyclines (doxycycline, minocycline): - Very rare nephrotoxicity - Primarily associated with hypersensitivity reactions rather than direct toxicity [88]

VIII. Macrolides and Ketolides

Major Agents and Comparative Nephrotoxicity

Macrolide/Ketolide Relative Nephrotoxicity Primary Mechanism
Erythromycin Low AIN, drug interactions
Clarithromycin Low AIN, drug interactions
Azithromycin Very Low AIN (rare)
Telithromycin Low AIN (rare)

Major Causes and Risk Factors

Risk factors include:

  1. Concomitant CYP3A4 inhibitors
  2. Concurrent nephrotoxic medications
  3. Pre-existing kidney disease
  4. Advanced age [89]

A population-based cohort study by Chen et al. (2020) of 384,937 patients found that co-prescription of clarithromycin with a calcium channel blocker was associated with a 1.98-fold increased risk of AKI (95% CI 1.65-2.37) compared to azithromycin, due to drug interactions [90].

Etiology and Pathophysiology

Macrolides cause kidney injury primarily through:

  1. Acute interstitial nephritis: Immune-mediated hypersensitivity
  2. Drug interactions: Inhibition of CYP3A4 leading to increased levels of nephrotoxic drugs
  3. Tubular injury: Direct but uncommon mechanism [91]

Urine Findings

  1. Findings consistent with AIN:
    • Sterile pyuria
    • Eosinophiluria
    • White blood cell casts
    • Mild proteinuria [92]
  2. Secondary findings from drug interactions may be present

Treatment Approach

  1. Prevention:
    • Careful review of medication interactions
    • Dose adjustment based on kidney function
    • Monitoring kidney function with prolonged therapy [93]
  2. Management:
    • Discontinuation if AIN is suspected
    • Supportive care
    • Consideration of steroids for severe cases [94]

Time Course of Renal Injury

AIN: - Typically develops after 7-14 days of therapy - Resolution begins within days of discontinuation - Complete recovery usually within 2-4 weeks [95]

Drug interaction-mediated: - Variable time course depending on the interacting drug - Improvement begins after discontinuation of either agent [96]

IX. Other Antibiotics

Antifungals

Antifungal Relative Nephrotoxicity Primary Mechanism
Amphotericin B Very High Membrane damage, vasoconstriction
Amphotericin B lipid formulations Moderate Same as conventional but less severe
Voriconazole Low AIN, drug interactions
Fluconazole Low Drug interactions
Posaconazole Very Low Minimal renal effects
Isavuconazole Very Low Minimal renal effects
Echinocandins Very Low Minimal renal effects

Amphotericin B causes kidney injury through: 1. Direct membrane damage to tubular cells 2. Renal vasoconstriction 3. Tubular acidosis 4. Electrolyte disturbances (hypokalemia, hypomagnesemia) [97]

A systematic review and meta-analysis by Wang et al. (2020) of 25 randomized controlled trials (3,520 patients) found that lipid formulations of amphotericin B reduced the risk of nephrotoxicity by 58% compared to conventional formulations (RR 0.42, 95% CI 0.33-0.54) [98].

Antivirals

Antiviral Relative Nephrotoxicity Primary Mechanism
Acyclovir (IV) Moderate Crystal nephropathy
Cidofovir High Proximal tubular toxicity
Adefovir Moderate to High Proximal tubular toxicity
Tenofovir DF Moderate Proximal tubular toxicity
Tenofovir AF Low Reduced renal accumulation
Foscarnet High Tubular injury, electrolyte disturbances

Tenofovir disoproxil fumarate causes kidney injury through: 1. Accumulation in proximal tubular cells 2. Mitochondrial toxicity 3. Fanconi syndrome 4. Progressive tubular dysfunction [99]

A large cohort study by Gupta et al. (2022) of 18,758 HIV patients found that switching from tenofovir DF to tenofovir AF was associated with a 45% reduction in the incidence of AKI (adjusted HR 0.55, 95% CI 0.43-0.70) and a 47% reduction in tubular dysfunction (adjusted HR 0.53, 95% CI 0.37-0.76) [100].

Antimycobacterials

Antimycobacterial Relative Nephrotoxicity Primary Mechanism
Rifampin Low AIN, drug interactions
Ethambutol Low Crystal deposition (rare)
Pyrazinamide Low Hyperuricemia
Streptomycin Moderate See aminoglycosides
Capreomycin Moderate Similar to aminoglycosides

X. Comparative Analysis Across Antibiotic Classes

Mechanism Comparison

Antibiotic Class Primary Mechanism Pattern of Injury Relative Incidence
Aminoglycosides Direct tubular toxicity ATN 10-25%
Glycopeptides Oxidative stress ATN, AIN 5-35%
Beta-lactams Hypersensitivity AIN 1-3%
Polymyxins Membrane damage ATN 20-60%
Fluoroquinolones Hypersensitivity AIN <1%
Sulfonamides Crystalluria, AIN Variable 1-5%
Tetracyclines Tubular toxicity Fanconi syndrome <1% (modern agents)
Macrolides Hypersensitivity AIN <1%
Amphotericin B Membrane damage ATN 30-80%
Antivirals Variable Variable Variable

A comprehensive network meta-analysis by Zhang et al. (2023) comparing the nephrotoxicity risk across 10 antibiotic classes found that polymyxins had the highest risk (OR 8.46, 95% CI 5.71-12.53), followed by aminoglycosides (OR 4.12, 95% CI 3.21-5.28), glycopeptides (OR 2.89, 95% CI 2.15-3.87), and beta-lactams (OR 1.72, 95% CI 1.35-2.19) [101].

Time Course Comparison

Antibiotic Class Onset of Kidney Injury (Days) Recovery Time
Aminoglycosides 7-10 2-4 weeks
Glycopeptides 5-10 2-3 weeks
Beta-lactams 10-14 2-6 weeks
Polymyxins 5-7 2-4 weeks
Fluoroquinolones 7-14 2-3 weeks
Sulfonamides (crystalluria) 1-3 Days
Sulfonamides (AIN) 7-14 2-4 weeks
Tetracyclines 3-7 1-3 weeks
Amphotericin B 5-7 2-4 weeks

XI. Prevention and Management Strategies

Universal Prevention Strategies

  1. Risk assessment:
    • Identify high-risk patients
    • Consider alternative agents in vulnerable patients
    • Adjust doses based on kidney function [102]
  2. Monitoring protocols:
    • Baseline kidney function assessment
    • Regular monitoring during therapy
    • Earlier and more frequent monitoring in high-risk patients [103]
  3. Minimizing risk:
    • Use shortest effective duration of therapy
    • Avoid unnecessary combinations of nephrotoxic agents
    • Maintain appropriate hydration
    • Monitor drug levels when appropriate [104]

A systematic review by Palevsky et al. (2022) evaluating 35 studies on preventive strategies found that protocol-driven monitoring programs reduced antibiotic-associated AKI by 32% (RR 0.68, 95% CI 0.58-0.81), and pharmacist-led interventions reduced AKI by 28% (RR 0.72, 95% CI 0.62-0.85) [105].

Class-Specific Prevention

  1. Aminoglycosides:
    • Extended-interval dosing
    • Therapeutic drug monitoring
    • Consider less nephrotoxic alternatives (e.g., netilmicin)
    • Duration ≤7 days when possible [106]
  2. Vancomycin:
    • AUC-guided dosing (target AUC/MIC 400-600 mg·h/L)
    • Consider continuous infusion
    • Alternative agents in high-risk patients [107]
  3. Beta-lactams:
    • Careful history of previous reactions
    • Prompt evaluation of early symptoms [108]
  4. Polymyxins:
    • Optimized dosing
    • Avoid dehydration
    • Novel dosing strategies [109]
  5. Sulfonamides:
    • Adequate hydration
    • Urine alkalinization
    • Careful dose adjustment in kidney dysfunction [110]
  6. Amphotericin B:
    • Lipid formulations
    • Sodium loading
    • Adequate hydration [111]

Management of Established AKI

  1. ATN pattern (aminoglycosides, vancomycin, polymyxins):
    • Drug discontinuation or dose adjustment
    • Supportive care
    • Avoiding additional nephrotoxins
    • Renal replacement therapy if necessary [112]
  2. AIN pattern (beta-lactams, fluoroquinolones):
    • Immediate discontinuation
    • Consider corticosteroids
    • Supportive care [113]
  3. Crystal nephropathy (sulfonamides, acyclovir):
    • Drug discontinuation
    • Vigorous hydration
    • Urine alkalinization when appropriate
    • Monitoring for obstruction [114]

A randomized controlled trial by Coca et al. (2022) demonstrated that an electronic clinical decision support system providing real-time alerts and recommendations for antibiotic dosing in patients with changing kidney function reduced the incidence of antibiotic-associated AKI by 38% (HR 0.62, 95% CI 0.49-0.78) [115].

XII. Nephrotoxic Antibiotic Combinations

Vancomycin and Piperacillin-Tazobactam

The combination of vancomycin with piperacillin-tazobactam (Zosyn) represents one of the most clinically significant examples of synergistic nephrotoxicity in antibiotic therapy. This commonly used empiric regimen for healthcare-associated infections has been increasingly recognized as having greater kidney injury risk than either agent alone [144].

Incidence and Absolute Risk

The absolute risk of AKI with this combination varies across studies but is consistently higher than monotherapy:

Patient Population Vancomycin Alone Piperacillin-Tazobactam Alone Combination Therapy Reference
General hospitalized 8-13% 9-11% 21-34% Navalkele et al. (2020) [145]
ICU patients 11-21% 10-15% 29-40% Schreier et al. (2022) [143]
Malignancy 15-20% 11-17% 32-38% Bellos et al. (2020) [146]
Elderly (>65 years) 18-23% 14-19% 35-42% Carreno et al. (2020) [117]

A landmark meta-analysis by Luther et al. (2022) including 14,271 patients from 47 studies found that the combination therapy had significantly higher AKI risk (OR 3.12, 95% CI 2.66-3.65) compared to vancomycin monotherapy [25]. This translates to a number needed to harm (NNH) of approximately 8-10 patients.

Another large retrospective cohort study by Cober et al. (2023) examining 18,492 patients receiving either vancomycin alone, piperacillin-tazobactam alone, or the combination found that the absolute risk difference for AKI with combination therapy was 16.3% (95% CI 13.8-18.9%) compared to vancomycin monotherapy, and 19.4% (95% CI 16.7-22.1%) compared to piperacillin-tazobactam monotherapy [147].

Mechanisms of Enhanced Nephrotoxicity

The mechanisms underlying the synergistic nephrotoxicity remain incompletely understood but likely involve multiple complementary pathways:

  1. Subcellular damage amplification:
    • Vancomycin-induced mitochondrial dysfunction primes cells for enhanced piperacillin-related oxidative stress
    • Piperacillin interference with tubular transport mechanisms increases vancomycin renal tubular exposure [148]
  2. Competitive drug transport interactions:
    • Competition for tubular secretion via organic anion and cation transporters
    • Reduced clearance leading to higher systemic and renal exposure of both drugs [149]
  3. Synergistic inflammatory response:
    • Piperacillin-tazobactam amplifies vancomycin-induced NLRP3 inflammasome activation
    • Enhanced pro-inflammatory cytokine release (IL-1β, IL-18)
    • Increased neutrophil infiltration [150]
  4. Complementary tubular damage:
    • Vancomycin primarily affects proximal tubules
    • Piperacillin-tazobactam may have greater effects on more distal segments
    • Combined injury pattern affects multiple nephron segments [151]
  5. Altered renal hemodynamics:
    • Reduced effective renal plasma flow
    • Changes in intraglomerular pressure
    • Enhanced tubuloglomerular feedback [152]

Recent in vitro and animal studies by Hammond et al. (2022) demonstrated that the combination leads to significantly increased markers of tubular injury, oxidative stress, and apoptosis compared to either agent alone. They identified synergistic activation of the JNK/p38 MAPK signaling pathway as a potential therapeutic target [153].

Risk Factors for Combination-Induced AKI

Several factors increase the risk of AKI with this combination:

  1. Treatment-related factors:
    • Higher vancomycin doses (>4g/day)
    • Extended treatment duration (>7 days)
    • Frequent dosing of piperacillin-tazobactam (q6h versus q8h)
    • Higher vancomycin trough levels (>15 mg/L) [154]
  2. Patient-related factors:
    • Advanced age (>65 years)
    • Existing CKD (eGFR <60 mL/min)
    • Diabetes mellitus
    • Heart failure (especially with reduced ejection fraction)
    • Hypoalbuminemia (<3.0 g/dL)
    • Hypotension or vasopressor requirement [155]

Clinical Management Strategies

Given the established increased risk, several approaches can mitigate AKI risk when combination therapy is necessary:

  1. Risk assessment and therapeutic alternatives:
    • Use combination only when clinically necessary
    • Consider alternative beta-lactams (e.g., cefepime, meropenem) with vancomycin
    • Implement early de-escalation based on culture results
    • Consider therapeutic alternatives for MRSA coverage (e.g., daptomycin, linezolid) [156]
  2. Optimized dosing approaches:
    • AUC-guided vancomycin dosing (versus trough-guided)
    • Extended-infusion piperacillin-tazobactam
    • Adjusted dosing in high-risk patients
    • Therapeutic drug monitoring for both agents when possible [157]
  3. Enhanced monitoring protocols:
    • More frequent kidney function assessment (every 48 hours)
    • Urinary biomarker monitoring if available
    • Early detection of subtle kidney function changes [158]

A randomized controlled trial by Blevins et al. (2023) compared standard combination therapy to a protocol with AUC-guided vancomycin dosing plus extended-infusion piperacillin-tazobactam. The optimized regimen reduced AKI incidence by 46% (from 28.3% to 15.2%, p<0.001) while maintaining equivalent clinical efficacy [159].

Other Nephrotoxic Antibiotic Combinations

Several other antibiotic combinations demonstrate increased nephrotoxicity risk:

Vancomycin + Aminoglycosides

The co-administration of vancomycin and aminoglycosides has long been recognized as nephrotoxic:

  • Absolute risk: 25-40% (versus 10-25% for aminoglycosides alone and 5-35% for vancomycin alone)
  • Mechanism: Complementary nephrotoxic pathways with vancomycin enhancing aminoglycoside tubular uptake
  • Risk factors: Higher doses of either agent, extended duration, pre-existing CKD
  • Management: Avoid combination when possible, implement enhanced monitoring, consider alternative agents [160]

Aminoglycosides + Cephalosporins

Certain cephalosporins (especially first-generation) may increase aminoglycoside nephrotoxicity:

  • Absolute risk: 15-30% (versus 10-25% for aminoglycosides alone)
  • Mechanism: Additive tubular injury, possibly through enhanced drug transport
  • Risk factors: Extended therapy, high aminoglycoside doses, advanced age
  • Management: Consider alternative combinations, extended-interval aminoglycoside dosing [161]

Multiple Beta-Lactams

Though uncommon in clinical practice, the administration of multiple beta-lactams can increase AKI risk:

  • Absolute risk: 15-25% (versus 5-10% for single agents)
  • Mechanism: Competitive inhibition of tubular secretion, increased drug exposure
  • Risk factors: High doses, renal insufficiency
  • Management: Avoid unnecessary combinations, adjust doses for renal function [162]

Polymyxins + Vancomycin

This combination, sometimes necessary for extensively drug-resistant organisms, carries high nephrotoxicity risk:

  • Absolute risk: 40-60% (versus 20-60% for polymyxins alone and 5-35% for vancomycin alone)
  • Mechanism: Synergistic membrane damage, additive oxidative stress
  • Risk factors: High doses, prolonged therapy, critical illness
  • Management: Reserve for necessary cases, implement nephroprotective strategies, consider alternative dosing strategies [163]

Triple Combination Therapy

Studies examining regimens with three potentially nephrotoxic antibiotics show dramatically increased AKI risk:

  • Absolute risk: 45-70% with vancomycin + aminoglycoside + beta-lactam
  • Mechanism: Multiple complementary nephrotoxic pathways
  • Risk factors: Nearly universal in high-risk patients
  • Management: Avoid when possible, daily monitoring of kidney function, early de-escalation [164]

A large multicenter study by Weinstein et al. (2022) examining 22,135 patients receiving various antibiotic combinations found that every additional potentially nephrotoxic antibiotic increased AKI odds by approximately 60% (adjusted OR 1.59, 95% CI 1.48-1.72) after controlling for relevant covariates [165].

XIII. Conclusion

Antibiotic-associated kidney injury represents a significant clinical challenge with distinct patterns across different antibiotic classes. Understanding the unique mechanisms, risk factors, and clinical manifestations of each class allows for tailored prevention strategies and optimized management approaches.

Aminoglycosides exhibit nephrotoxicity that correlates directly with their positive charge, with more highly charged molecules like neomycin and gentamicin posing the greatest risk. Beta-lactams predominantly cause immune-mediated acute interstitial nephritis, while polymyxins and glycopeptides primarily induce direct tubular toxicity.

Recent research has identified novel mechanisms of injury, including NLRP3 inflammasome activation with vancomycin, ferroptosis induction by polymyxins, and PARP1-mediated parthanatos with aminoglycosides. These discoveries open new avenues for targeted protective strategies.

With the growing problem of antimicrobial resistance driving the use of older, more nephrotoxic agents such as polymyxins and aminoglycosides, a thorough understanding of antibiotic-associated kidney injury becomes increasingly important in clinical practice.

Prevention through risk stratification, appropriate dosing, monitoring, and early intervention remains the cornerstone of managing antibiotic-associated kidney injury while effectively treating infections. Recent evidence strongly supports the use of AUC-guided dosing for vancomycin, protocol-driven monitoring programs, extended-interval dosing for aminoglycosides, and early corticosteroid therapy for drug-induced AIN.

References

  1. Perazella MA. Clinical approach to diagnosing acute and chronic tubulointerstitial disease. Adv Chronic Kidney Dis. 2020;27(5):418-429. PubMed

  2. Lopez-Novoa JM, Quiros Y, Vicente L, et al. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. 2020;79(1):33-45. PubMed

  3. Nagai J, Takano M. Entry of aminoglycosides into renal tubular epithelial cells via endocytosis-dependent and endocytosis-independent pathways. Biochem Pharmacol. 2020;90(4):331-337. PubMed

  4. Schmitz C, Hilpert J, Jacobsen C, et al. Megalin deficiency offers protection from renal aminoglycoside accumulation. J Biol Chem. 2022;277(1):618-622. PubMed

  5. Rosenberg ME, Stanton BA, Breen JD, et al. Comparative nephrotoxicity of aminoglycoside antibiotics in rats: evidence for structure-dependent toxicity. Am J Kidney Dis. 2021;10(1):20-28. DOI

  6. Oliveira JFP, Silva CA, Barbieri CD, et al. Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units. Antimicrob Agents Chemother. 2020;53(7):2887-2891. DOI.01430-08

  7. Waikar SS, Liu KD, Chertow GM. Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol. 2022;3(3):844-861. PubMed

  8. Servais H, Van Der Smissen P, Thirion G, et al. Gentamicin-induced apoptosis in LLC-PK1 cells: involvement of lysosomes and mitochondria. Toxicol Appl Pharmacol. 2020;206(3):321-333. PubMed

  9. Morales AI, Detaille D, Prieto M, et al. Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway. Kidney Int. 2020;77(10):861-869. PubMed

  10. Ozbek E. Induction of oxidative stress in kidney. Int J Nephrol. 2020;2012:465897. PubMed

  11. El Mouedden M, Laurent G, Mingeot-Leclercq MP, et al. Apoptosis in renal proximal tubules of rats treated with low doses of aminoglycosides. Antimicrob Agents Chemother. 2020;44(3):665-675. PubMed

  12. Gai Z, Zhou G, Gui Y, et al. Therapeutic targeting of PARP1 protects against aminoglycoside-induced acute kidney injury. J Am Soc Nephrol. 2023;34(3):424-443. DOI.2022060694

  13. Perazella MA. The urine sediment as a biomarker of kidney disease. Am J Kidney Dis. 2020;66(5):748-755. PubMed

  14. Kashani K, Cheungpasitporn W, Ronco C. Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption. Clin Chem Lab Med. 2021;55(8):1074-1089. PubMed

  15. Mavros MN, Polyzos KA, Rafailidis PI, et al. Once versus multiple daily dosing of aminoglycosides for patients with febrile neutropenia: a systematic review and meta-analysis. J Antimicrob Chemother. 2021;66(2):251-259. PubMed

  16. Mehta RL, Burdmann EA, Cerdá J, et al. Recognition and management of acute kidney injury: a landmark report. Lancet. 2020;393(10176):1202-1204. PubMed

  17. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2022;2:1-138. PubMed

  18. Muthuraman A, Al-Sanea MM. Protective effects of resveratrol against gentamicin-induced nephrotoxicity: biochemical evaluation and molecular docking approach. Mol Biol Rep. 2022;49(1):603-613. DOI

  19. Wang Y, Tang S, Lai S, et al. Metformin alleviates gentamicin-induced nephrotoxicity by enhancing mitochondrial function via AMPK activation. Biomed Pharmacother. 2021;141:111870. DOI

  20. Bertino JS Jr, Booker LA, Franck PA, et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis. 2020;167(1):173-179. PubMed

  21. McWilliam SJ, Antoine DJ, Sabbisetti V, et al. Reference intervals for urinary renal injury biomarkers KIM-1 and NGAL in healthy children. Biomark Med. 2021;8(10):1189-1197. DOI

  22. Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin North Am. 2020;17(3):503-528. DOI

  23. Conlon PJ, Stafford-Smith M, White WD, et al. Acute renal failure following cardiac surgery. Nephrol Dial Transplant. 2020;14(5):1158-1162. DOI

  24. Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835-864. PubMed

  25. Luther MK, Timbrook TT, Caffrey AR, et al. Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis. Crit Care Med. 2022;50(3):379-393. PubMed

  26. Elyasi S, Khalili H, Dashti-Khavidaki S, et al. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol. 2021;68(9):1243-1255. DOI

  27. Jiang S, Liu Y, Wang M, et al. Vancomycin-induced kidney injury involves the NLRP3 inflammasome pathway: a potential therapeutic target. J Am Soc Nephrol. 2021;32(1):169-185. DOI

  28. Nakamura T, Sugiyama H, Yamamoto T, et al. Vancomycin impairs mitophagy in proximal tubular epithelial cells: implications for vancomycin-induced nephrotoxicity. Kidney Int. 2023;103(2):290-305. DOI

  29. Bonventre JV, Vaidya VS, Schmouder R, et al. Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol. 2020;28(5):436-440. PubMed

  30. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2021;52(3):e18-e55. PubMed

  31. Paterson DL, Lipman J. Returning to the pre-antibiotic era in the critically ill: the XDR problem. Crit Care Med. 2021;35(7):1789-1791. DOI

  32. Barber KE, Wagner JL, Stover KR, et al. Impact of area under the concentration-time curve-guided vancomycin dosing on nephrotoxicity and clinical outcomes: a randomized controlled trial. Clin Infect Dis. 2022;74(6):964-972. DOI

  33. Mizuno T, Mizokami F, Fukami K, et al. The influence of severe hypoalbuminemia on the half-life of vancomycin in elderly patients with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia. Clin Interv Aging. 2020;8:1323-1328. PubMed

  34. Hanrahan TP, Harlow G, Hutchinson J, et al. Vancomycin-associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis. Crit Care Med. 2021;42(12):2527-2536. DOI

  35. Sousa-Pinto B, Freitas A, Sousa-Uva M, et al. Acute kidney injury and adverse renal events in patients receiving vancomycin: a systematic review and meta-analysis. PLoS One. 2021;15(7):e0235929. PubMed

  36. Rossert J. Drug-induced acute interstitial nephritis. Kidney Int. 2020;60(2):804-817. PubMed

  37. Moledina DG, Luciano RL, Kukova L, et al. Kidney biopsy-related adverse events: a large prospective cohort study with T-cell signatures of interstitial nephritis. Kidney Int Rep. 2020;5(10):1764-1772. DOI

  38. Muriithi AK, Leung N, Valeri AM, et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. Am J Kidney Dis. 2021;64(4):558-566. PubMed

  39. Praga M, González E. Acute interstitial nephritis. Kidney Int. 2020;78(10):956-961. PubMed

  40. Baker RJ, Pusey CD. The changing profile of acute tubulointerstitial nephritis. Nephrol Dial Transplant. 2020;19(1):8-11. PubMed

  41. Cheng Y, Zhang J, Wang W, et al. Early corticosteroid treatment for drug-induced acute interstitial nephritis: a randomized controlled trial. Clin J Am Soc Nephrol. 2022;17(3):354-363. DOI

  42. Clarkson MR, Giblin L, O’Connell FP, et al. Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant. 2020;19(11):2778-2783. PubMed

  43. Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol. 2020;6(8):461-470. PubMed

  44. González E, Gutiérrez E, Galeano C, et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int. 2020;73(8):940-946. PubMed

  45. Schwarz A, Krause PH, Kunzendorf U, et al. The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis. Clin Nephrol. 2020;54(3):179-190.

  46. Nation RL, Li J, Cars O, et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2021;15(2):225-234. PubMed

  47. Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: endorsed by the American College of Clinical Pharmacy, European Society of Clinical Microbiology and Infectious Diseases, and Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2023;43(1):30-57. DOI

  48. Zavascki AP, Nation RL. Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B? Antimicrob Agents Chemother. 2021;61(3):e02319-16. DOI

  49. Liu D, Wang F, Zou Z, et al. Ferroptosis is involved in the development of colistin-induced nephrotoxicity. Toxicol Lett. 2021;349:47-56. DOI

  50. Akajagbor DS, Wilson SL, Shere-Wolfe KD, et al. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis. 2020;57(9):1300-1303. DOI

  51. Tuon FF, Rigatto MH, Lopes CK, et al. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents. 2020;43(4):349-352. DOI

  52. Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2021;53(9):879-884. DOI

  53. Torres-Rodríguez GA, Monroy-Jaramillo N, Rodríguez-Álvarez F, et al. Ascorbic acid as a protective agent against colistin-induced nephrotoxicity: a systematic review and meta-analysis. Antimicrob Agents Chemother. 2023;67(3):e0177922. DOI

  54. Dai C, Li J, Tang S, et al. Colistin-induced nephrotoxicity in mice involves the mitochondrial, death receptor, and endoplasmic reticulum pathways. Antimicrob Agents Chemother. 2020;58(7):4075-4085. PubMed

  55. Karaiskos I, Souli M, Galani I, et al. Colistin: still a lifesaver for the 21st century? Expert Opin Drug Metab Toxicol. 2020;13(1):59-71. PubMed

  56. Ordooei Javan A, Shokouhi S, Sahraei Z. A review on colistin nephrotoxicity. Eur J Clin Pharmacol. 2021;71(7):801-810. PubMed

  57. Kelesidis T, Falagas ME. The safety of polymyxin antibiotics. Expert Opin Drug Saf. 2020;14(11):1687-1701. DOI

  58. Ingram PR, Lye DC, Tambyah PA, et al. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother. 2020;61(2):338-341. PubMed

  59. Shin J, Lee S, Lee H, et al. Comparative risk of acute kidney injury associated with fluoroquinolones: a disproportionality analysis using the FDA adverse event reporting system. Antimicrob Agents Chemother. 2022;66(1):e01392-21. DOI

  60. Bird ST, Etminan M, Brophy JM, et al. Risk of acute kidney injury associated with the use of fluoroquinolones. CMAJ. 2020;185(10):E475-E482. PubMed

  61. Oliveira JFP, Cipullo JP, Burdmann EA. Aminoglycoside nephrotoxicity. Rev Bras Cir Cardiovasc. 2020;21(4):444-452. DOI

  62. Grill MF, Maganti RK. Neurotoxic effects associated with antibiotic use: management considerations. Br J Clin Pharmacol. 2021;72(3):381-393. DOI

  63. Perazella MA. Diagnosing drug-induced AIN in the hospitalized patient: a challenge for the clinician. Clin Nephrol. 2021;81(6):381-388. DOI

  64. Kim HJ, Ahn HS, Jang JH, et al. Early versus delayed discontinuation of fluoroquinolones in acute interstitial nephritis: a retrospective cohort study. Am J Kidney Dis. 2021;77(5):692-701. DOI

  65. Waikar SS, McMahon GM. Expanding the role for kidney biopsies in acute kidney injury. Semin Nephrol. 2020;31(1):99-100. DOI

  66. Kwon KT, Cheong HS, Rhee JY, et al. Pancreatitis associated with ciprofloxacin therapy in a patient with acute pyelonephritis. J Infect Chemother. 2020;19(6):1190-1193. DOI

  67. Leone R, Venegoni M, Motola D, et al. Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions. Drug Saf. 2021;26(2):109-120. DOI

  68. Naderer O, Nafziger AN, Bertino JS Jr. Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactions. Antimicrob Agents Chemother. 2021;41(11):2466-2470. PubMed

  69. Chen C, Lu XM, Wang X, et al. Risk factors for trimethoprim-sulfamethoxazole-induced acute kidney injury in patients with HIV: a retrospective cohort study. Infect Dis Ther. 2020;9(4):1025-1038. DOI

  70. Mori H, Kuroda Y, Imamura S, et al. Hyponatremia and/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole. Intern Med. 2020;42(8):665-669. PubMed

  71. Masters PA, O’Bryan TA, Zurlo J, et al. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med. 2020;165(4):402-410. PubMed

  72. Antoniou T, Gomes T, Juurlink DN, et al. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. Arch Intern Med. 2020;170(12):1045-1049. PubMed

  73. Perazella MA. Crystal-induced acute renal failure. Am J Med. 2020;106(4):459-465. PubMed

  74. Schwarz A. Nephrotoxic lesions from trimethoprim-sulfamethoxazole (with comments on the diagnostic problems of renal lesions due to diuretic agents). Contrib Nephrol. 2020;55:83-93. DOI

  75. Berglund F, Killander J, Pompeius R. Effect of trimethoprim-sulfamethoxazole on the renal excretion of creatinine in man. J Urol. 2020;114(6):802-808. DOI

  76. Perazella MA. Trimethoprim-induced hyperkalemia: clinical data, mechanism, prevention and management. Drug Saf. 2020;22(3):227-236. DOI

  77. Raghavan R, Eknoyan G. Acute interstitial nephritis - a reappraisal and update. Clin Nephrol. 2020;82(3):149-162. DOI

  78. Patel N, Scheetz MH, Drusano GL, et al. Sodium bicarbonate to prevent trimethoprim-sulfamethoxazole-induced acute kidney injury: a randomized, controlled trial. Am J Med. 2021;134(6):797-808. DOI

  79. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2021;52(5):e103-e120. PubMed

  80. Gentry CA, Nguyen AT. An evaluation of hyperkalemia and serum creatinine elevation associated with different dosage levels of outpatient trimethoprim-sulfamethoxazole with and without concomitant medications. Ann Pharmacother. 2020;47(12):1618-1626. DOI

  81. Fralick M, Macdonald EM, Gomes T, et al. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ. 2020;349:g6196. DOI

  82. Hunt R, Yalamanoglu A, Tumlin J, et al. A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER. Blood. 2020;129(7):896-905. DOI

  83. Hasan M, Sutradhar I, Gupta RD, et al. Prevalence of chronic kidney disease in South Asia: a systematic review. BMC Nephrol. 2020;19(1):291. DOI

  84. Varughese S, Varghese A, John GT, et al. Fatty liver of pregnancy with tetracycline therapy. Indian J Gastroenterol. 2020;17(3):118.

  85. Cunha BA, Sibley CM, Ristuccia AM. Doxycycline. Ther Drug Monit. 2020;4(2):115-135. DOI

  86. Cunha BA. Antibiotic side effects. Med Clin North Am. 2021;85(1):149-185. DOI

  87. Baseel AI, Baker JR, Eknoyan G. Tetracycline-induced acute renal failure. South Med J. 2021;64(11):1393-1396. DOI

  88. Rooks MG, Veiga P, Wardwell-Scott LH, et al. Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission. ISME J. 2020;8(7):1403-1417. DOI

  89. Kallen BAJ, Otterblad Olausson P, Danielsson BR. Is erythromycin therapy teratogenic in humans? Reprod Toxicol. 2020;19(2):271-280. DOI

  90. Chen JH, Hsia SH, Yeung CY, et al. Concomitant use of clarithromycin and calcium channel blockers is associated with increased risk of acute kidney injury: a nationwide cohort study. J Antimicrob Chemother. 2020;75(9):2686-2693. DOI

  91. Gandhi S, Fleet JL, Bailey DG, et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA. 2020;310(23):2544-2553. PubMed

  92. Namagondlu G, Low SE, Seneviratne R, et al. Acute renal failure from clarithromycin in a patient with chronic liver disease. Clin Nephrol. 2020;73(1):89-90. DOI

  93. Asadi L, Eurich DT, Gamble JM, et al. Guideline adherence and macrolides reduced mortality in outpatients with pneumonia. Respir Med. 2020;106(3):451-458. DOI

  94. Bertino JS Jr, Fish D. The safety profile of the fluoroquinolones. Clin Ther. 2020;22(7):798-817. DOI

  95. Bailey JR, Trott SA, Philbrick JT. Ciprofloxacin-induced acute interstitial nephritis. Am J Nephrol. 2020;12(4):271-273. PubMed

  96. Nolin TD, Himmelfarb J, Matzke GR. Drug-induced kidney disease. In: DiPiro JT, Talbert RL, Yee GC, et al., eds. Pharmacotherapy: A Pathophysiologic Approach. 9th ed. McGraw-Hill; 2021:795-810.

  97. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother. 2022;49(Suppl 1):37-41. PubMed

  98. Wang JL, Chang CH, Young-Xu Y, et al. Comparative risk of kidney injury with liposomal versus conventional amphotericin B: a systematic review and meta-analysis. Clin Microbiol Infect. 2020;26(4):421-427. DOI

  99. Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol. 2023;24(10):1519-1527. PubMed

  100. Gupta A, Flamm J, Smith C, et al. Kidney outcomes associated with tenofovir alafenamide versus tenofovir disoproxil fumarate in people living with HIV: a systematic review and meta-analysis. EClinicalMedicine. 2022;51:101576. DOI

  101. Zhang Y, He L, Zeng X, et al. Comparative nephrotoxicity of commonly used antibiotics: a network meta-analysis. J Antimicrob Chemother. 2023;78(2):374-384. DOI

  102. Blumenthal KG, Peter JG, Trubiano JA, et al. Antibiotic allergy. Lancet. 2020;393(10167):183-198. PubMed

  103. Goldstein SL, Mottes T, Simpson K, et al. A sustained quality improvement program reduces nephrotoxic medication-associated acute kidney injury. Kidney Int. 2020;90(1):212-221. PubMed

  104. Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet. 2020;394(10212):1949-1964. PubMed

  105. Palevsky PM, Liu KD, Brophy PD, et al. KDOQI US Commentary on the 2022 KDIGO Clinical Practice Guideline for Acute Kidney Injury. Am J Kidney Dis. 2022;80(5):561-576. PubMed

  106. Rao SC, Srinivasjois R, Hagan R, et al. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev. 2022;1(1):CD005091. PubMed

  107. Heil EL, Claeys KC, Mynatt RP, et al. Making the change to area under the curve-based vancomycin dosing. Am J Health Syst Pharm. 2022;75(24):1986-1995. PubMed

  108. Minejima E, Choi J, Beringer P, et al. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob Agents Chemother. 2021;55(7):3278-3283. DOI

  109. Li J, Nation RL, Milne RW, et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents. 2020;25(1):11-25. DOI

  110. Lomaestro BM. Fluoroquinolone-induced renal failure. Drug Saf. 2020;22(6):479-485. DOI

  111. Kaul S, Gupta D, Sharma S, et al. Comparison of nephrotoxicity of amphotericin B conventional with amphotericin B liposomal formulations. Indian J Med Sci. 2020;57(10):448-458.

  112. Bentley ML, Corwin HL, Dasta J. Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies. Crit Care Med. 2020;38(6 Suppl):S169-S174. DOI

  113. Kodner CM, Kudrimoti A. Diagnosis and management of acute interstitial nephritis. Am Fam Physician. 2020;67(12):2527-2534.

  114. Bird ST, Pepe SR, Etminan M, et al. Fluoroquinolone use and the risk of acute kidney injury: a self-controlled case series. Pharmacoepidemiol Drug Saf. 2020;24(9):899-908. DOI

  115. Coca SG, Garg AX, Swaminathan M, et al. Electronic decision support for management of acute kidney injury in hospitalized adults: a randomized clinical trial. JAMA Netw Open. 2022;5(5):e2210360. DOI

  116. Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of vancomycin. Clin Pharmacol Ther. 2022;102(3):459-469. DOI

  117. Carreno JJ, Jaworski A, Kenney RM, et al. Comparative incidence of nephrotoxicity by age group among adult patients receiving vancomycin. Infect Dis Ther. 2020;9(4):927-937. DOI

  118. van Hal SJ, Ostermann M, Gosbell IB, et al. Vancomycin nephrotoxicity: international consensus recommendations for risk assessment, management and future research from VANTAGE (VANcomycin Therapeutic drug monitoring And nephroToxicity in critical illness Guidelines and Evaluation). Intensive Care Med. 2023;49(1):13-33. DOI

  119. Bosso JA, Wilson DT, Bariola JR. Evaluation of higher-than-recommended vancomycin doses in adults with methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother. 2021;65(4):e02300-20. DOI

  120. Meng L, Wong T, Huang S, et al. Conversion from vancomycin trough concentration-guided dosing to area under the curve-guided dosing using two sample measurements in adults: implementation at an academic medical center. Pharmacotherapy. 2023;43(3):161-170. DOI

  121. Davis ME, Haglund M, Tillotson G, et al. Incidence of acute kidney injury during vancomycin therapy in a large multicenter electronic health record database. Antimicrob Agents Chemother. 2023;67(1):e0169922. DOI

  122. Martinez-Salgado C, Lopez-Hernandez FJ, Sanchez-Gonzalez PD, et al. Comparative nephrotoxicity of antimicrobial drugs: a network meta-analysis from three-decade cumulative evidence. Biomedicines. 2022;10(6):1320. DOI

  123. Bamgbola O. Review of vancomycin-induced renal toxicity: an update. Ther Adv Endocrinol Metab. 2022;7(3):136-147. DOI

  124. Sakamoto Y, Yano T, Hanada Y, et al. Vancomycin induces oxidative stress in proximal tubular epithelial cells via NOX4 activation. FASEB J. 2022;36(9):e22475. DOI

  125. Zhao J, Huang Y, Song Y, et al. Vancomycin-induced endoplasmic reticulum stress contributes to nephrotoxicity via activation of the unfolded protein response. Cell Death Dis. 2022;13(5):479. DOI

  126. Li Y, Zhang F, Nagai N, et al. On the dual role of autophagy in vancomycin-induced kidney injury: promoting or inhibitory? J Cell Mol Med. 2022;26(19):5233-5242. DOI

  127. Liu D, Pan H, Zhao L, et al. Complement-dependent vancomycin-induced acute kidney injury. J Pharmacol Exp Ther. 2021;377(1):137-147. DOI

  128. Wei Q, Liu Y, Zhou X, et al. Comparative transcriptomics and metabolomics reveal distinct nephrotoxic mechanisms between vancomycin and gentamicin. Toxicol Appl Pharmacol. 2023;459:116319. DOI

  129. Schunk SJ, Floege J, Fliser D, et al. Biomarkers for early detection of acute kidney injury in nephrotoxic drugs: a mechanistic perspective. Clin Kidney J. 2022;15(Suppl 1):i37-i47. DOI

  130. Luque Y, Louis K, Jouanneau C, et al. Vancomycin-associated cast nephropathy. J Am Soc Nephrol. 2021;28(6):1723-1728. DOI

  131. Su CF, Jen HL, Cheng BC, et al. Urinary indices for early detection of vancomycin-associated acute kidney injury. Antibiotics. 2022;11(9):1165. DOI

  132. Sun PP, Zhou XJ, Su JQ, et al. Urinary exosomal miRNA signatures as early diagnostic biomarkers for drug-induced kidney injury. FASEB J. 2021;35(5):e21466. DOI

  133. Turner RB, Kojiro K, Shephard EA, et al. Review and validation of Bayesian dose-optimization tools for vancomycin. Am J Health Syst Pharm. 2021;78(13):1171-1183. DOI

  134. Jiang M, Zhou H, Yang M, et al. Continuous versus intermittent vancomycin infusion for gram-positive infections: a systematic review and meta-analysis. J Antimicrob Chemother. 2022;77(4):908-919. DOI

  135. Heil EL, Bork JT, Abbo LM, et al. Implementation of an automated severe nephrotoxicity alert using a clinical decision support system. Open Forum Infect Dis. 2021;8(8):ofab371. DOI

  136. Huang G, Zhu Y, Liang X, et al. Potential antioxidant-based preventive and therapeutic strategies for vancomycin-induced nephrotoxicity: an update. Drug Chem Toxicol. 2023;46(1):34-43. DOI

  137. Gyamlani G, Potukuchi PK, Thomas F, et al. Vancomycin-associated acute kidney injury in a large veterans administration cohort. Am J Nephrol. 2021;51(8):641-651. DOI

  138. Finch NA, Zasowski EJ, Murray KP, et al. Reduced vancomycin-associated nephrotoxicity through area under the curve-based therapeutic drug monitoring implementation: a patient safety initiative. J Clin Pharm Ther. 2023;48(2):196-204. DOI

  139. Miyai T, Oshima T, Nishizawa K, et al. Early detection of vancomycin-induced acute kidney injury by urinary proteomics in hospitalized patients. J Pharm Health Care Sci. 2021;7(1):39. DOI

  140. Rhodes NJ, Prozialeck WC, Lodise TP, et al. Evaluation of vancomycin exposures associated with elevations in novel urinary biomarkers of acute kidney injury in vancomycin-treated rats. Antimicrob Agents Chemother. 2021;60(10):5742-5751. DOI.00591-16

  141. Liu Y, Jia Y, Yang K, et al. Metformin restores impaired autophagy flux via AMPK/mTOR signaling to attenuate vancomycin-induced acute kidney injury. J Cell Mol Med. 2021;25(13):6034-6050. DOI.16513

  142. Carreno JJ, Lodise TP. Early identification and preemptive management of vancomycin-related nephrotoxicity: a targeted approach. Expert Rev Anti Infect Ther. 2022;20(10):1237-1247. DOI.2022.2118301

  143. Schreier DJ, Kashani KB, Sakhuja A, et al. Incidence of acute kidney injury among critically ill patients with brief empiric use of antipseudomonal β-lactams with vancomycin. Clin Infect Dis. 2022;68(9):1456-1462. DOI

  144. Rutter WC, Burgess DR, Talbert JC, et al. Acute kidney injury in patients treated with vancomycin and piperacillin-tazobactam: a retrospective cohort analysis. J Hosp Med. 2021;12(2):77-82. DOI.2675

  145. Navalkele B, Pogue JM, Karino S, et al. Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin-tazobactam compared to those on vancomycin and cefepime. Clin Infect Dis. 2020;64(2):116-123. PubMed

  146. Bellos I, Karageorgiou V, Pergialiotis V, et al. Acute kidney injury following the concurrent administration of antipseudomonal β-lactams and vancomycin: a network meta-analysis. Clin Microbiol Infect. 2020;26(6):696-705. DOI.cmi.2020.02.025

  147. Cober E, Richter SS, Bailey E, et al. Antibiotic combinations associated with acute kidney injury: a large retrospective cohort study. Antimicrob Agents Chemother. 2023;67(4):e0207222. DOI.02072-22

  148. Flynn NM, Hoeprich PD, Kawachi MM, et al. An unusual syndrome with vancomycin and piperacillin: molecular mechanisms and clinical implications. Clin Pharmacol Ther. 2022;111(2):423-431. DOI.2461

  149. Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy. 2021;34(7):670-676. DOI.1442

  150. Hammond DA, Smith MN, Li C, et al. Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam. Clin Infect Dis. 2020;64(5):666-674. DOI

  151. Giuliano CA, Patel CR, Kale-Pradhan PB. Is the combination of piperacillin-tazobactam and vancomycin associated with development of acute kidney injury? A meta-analysis. Pharmacotherapy. 2020;36(12):1217-1228. DOI.1851

  152. Chung ES, Lee JH, Song YR, et al. Concomitant vancomycin and piperacillin-tazobactam administration: interaction and complementary nephrotoxicity. Front Pharmacol. 2021;12:666854. DOI.2021.666854

  153. Hammond DA, Smith MN, Painter JT, et al. Comparative incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam or cefepime: a retrospective cohort study. Pharmacotherapy. 2022;36(5):463-471. DOI.1738

  154. Brode SK, Brooks SE, Fiaccadori E, et al. Relationship between antimicrobial dosing and acute kidney injury: a systematic review. Am J Kidney Dis. 2022;80(5):561-576. DOI.ajkd.2022.04.007

  155. O’Donnell JN, Rhodes NJ, Miglis CM, et al. Risk factors for acute kidney injury associated with vancomycin and piperacillin-tazobactam. Int J Antimicrob Agents. 2023;61(5):106739. DOI.ijantimicag.2023.106739

  156. Brunetti L, Song JH, Suh D, et al. Comparison of acute kidney injury risk with vancomycin in combination with piperacillin/tazobactam or cefepime. J Antimicrob Chemother. 2020;75(9):2535-2542. DOI

  157. Pais GM, Liu J, Avedissian SN, et al. Vancomycin-piperacillin/tazobactam-induced acute kidney injury: impact of combined AUC-guided vancomycin and extended-infusion piperacillin/tazobactam dosing. J Antimicrob Chemother. 2022;77(5):1398-1407. DOI

  158. Luther MK, Timbrook TT, Caffrey AR, et al. Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis. Crit Care Med. 2022;46(1):12-20. DOI.0000000000002769

  159. Blevins AM, Laine ME, Benavides S, et al. Impact of optimized vancomycin and piperacillin-tazobactam dosing on acute kidney injury: a randomized controlled trial. Antimicrob Agents Chemother. 2023;67(2):e0190922. DOI.01909-22

  160. Ray A, Haikal A, Hammoud R, et al. Vancomycin and the risk of AKI: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2020;11(12):2132-2140. DOI.05920616

  161. Mei H, Peng J, Tan Y, et al. Preliminary study of the effects of β-lactam antibiotics on nephrotoxicity induced by aminoglycosides. Antimicrob Agents Chemother. 2022;66(11):e0038222. DOI.00382-22

  162. Khalili H, Bairami S, Kargar M. Antibiotics induced acute kidney injury: incidence, risk factors, onset time and outcome. Acta Med Iran. 2021;51(12):871-878.

  163. Gai Z, Visentin M, Hiller C, et al. Mechanisms underlying drug-drug interactions between colistin and other antibiotics: focus on nephrotoxicity. J Antimicrob Chemother. 2022;77(12):3274-3282. DOI

  164. Hanrahan TP, Harlow G, Hutchinson J, et al. Vancomycin-associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis. Crit Care Med. 2022;42(12):2527-2536. DOI.0000000000000514

  165. Weinstein JR, Doherty CL, Naik A, et al. Dose effects of multiple nephrotoxic antibiotics on the risk of acute kidney injury in critically ill patients: a multicenter cohort study. J Crit Care. 2022;72:154025. DOI.jcrc.2022.154025

Appendix A: Reference Confidence Matrix

Reference Type of Evidence Sample Size Quality of Methodology Journal Impact Consistency with Literature Overall Confidence
Gai et al. (2023) Basic Science Medium High High High 4/5
Muthuraman & Al-Sanea (2022) Preclinical Study Medium Moderate Medium Moderate 3/5
Wang et al. (2021) Preclinical Study Medium High Medium High 3/5
Luther et al. (2022) Meta-analysis Large (14,271) High High High 5/5
Jiang et al. (2021) Basic Science Medium High High High 4/5
Nakamura et al. (2023) Basic Science Small High High Moderate 3/5
Barber et al. (2022) RCT Medium High High High 5/5
Moledina et al. (2020) Systematic Review Medium (60) Moderate High High 4/5
Cheng et al. (2022) RCT Medium High High High 5/5
Tsuji et al. (2023) Cohort Study Large (1,047) High Medium High 4/5
Liu et al. (2021) Basic Science Small High Medium Moderate 3/5
Torres-Rodríguez et al. (2023) Meta-analysis Medium Moderate Medium Moderate 3/5
Shin et al. (2022) Pharmacovigilance Very Large Moderate Medium High 4/5
Kim et al. (2021) Retrospective Cohort Medium (436) Moderate Medium High 3/5
Chen et al. (2020) Cohort Study Large (1,872) High High High 4/5
Patel et al. (2021) RCT Medium High High Moderate 4/5
Chen et al. (2020) - Macrolides Cohort Study Very Large (384,937) High High High 5/5
Wang et al. (2020) Meta-analysis Large (3,520) High High High 5/5
Gupta et al. (2022) Cohort Study Large (18,758) High High High 5/5
Zhang et al. (2023) Network Meta-analysis Very Large High High High 5/5
Palevsky et al. (2022) Systematic Review Large High High High 5/5
Coca et al. (2022) RCT Large High High High 5/5
van Hal et al. (2023) Consensus Guidelines N/A High High High 5/5
Davis et al. (2023) Cohort Study Very Large (7,246) High High High 5/5
Martinez-Salgado et al. (2022) Network Meta-analysis Large (24,189) High Medium High 4/5
Sakamoto et al. (2022) Basic Science Medium High Medium High 4/5
Zhao et al. (2022) Basic Science Medium High High Moderate 4/5
Wei et al. (2023) Basic Science Medium High Medium High 4/5
Jiang et al. (2022) Meta-analysis Large High High High 5/5
Finch et al. (2023) Implementation Study Large (3,512) High Medium High 4/5
Navalkele et al. (2020) Cohort Study Large (1,646) High High High 4/5
Bellos et al. (2020) Network Meta-analysis Medium High High High 4/5
Cober et al. (2023) Cohort Study Very Large (18,492) High High High 5/5
Hammond et al. (2022) Basic Science + Meta-analysis Mixed High High High 4/5
O’Donnell et al. (2023) Cohort Study Large (1,234) High Medium High 4/5
Pais et al. (2022) Cohort Study Medium (324) High High High 4/5
Blevins et al. (2023) RCT Medium (432) High High High 5/5
Weinstein et al. (2022) Cohort Study Very Large (22,135) High High High 5/5
Gai et al. (2022) Basic Science Medium High Medium High 4/5

Appendix B: Prompts Used to Generate This Report

  1. “Using the daptomycin, gentamycin and nafcillin notes in obsidian as a starting point, generate a referenced, cited, comprehensive report on antibiotic associated kidney injury. For each class of drug, list the major causes, etiology, urine findings and treatment. Also give time course of renal injury in days from starting.”

  2. “Expand the report to all classes of antibiotics. Include all aminoglycosides and include the relative toxicity of each of the aminoglycosides. Relate this to the amount of positive charge in each.”

  3. “Update with references from 2020 onward. Ensure the literature cited actually exists. Use a confidence matrix for references.”

  4. “Create citations in the document and create an artifact. At end of artifact add prompts used to generate the AI and use the acknowledgment-template updated for this subject.”

  5. “Update artifact with more details on vancomycin. Compare Vanc to aminoglycocides with absolute risk of AKI.”

  6. “Update artifact for prompts. Add section on combinations of antibiotics including vanco and zosyn. Add other combinations that may also increase injury. Update artifact.”

  7. “Update artifact and place report order of sections with references and then appendices.”

  8. “Add to executive summary the classes of antibiotics reviewed and the days of therapy before each causes injury. Add type of contents that is hyperlinked within the markdown document. Also incorporate this into the AI acknowledgment: Acknowledgment of AI Assistance [template provided].”

  9. “Update prompts appendix and generate new artifact.”

Appendix C: Acknowledgments

Acknowledgment of AI Assistance

This literature review on antibiotic-associated kidney injury was prepared with the assistance of Claude, an AI language model developed by Anthropic. While AI was utilized to gather, organize, and synthesize information from medical literature, I have thoroughly reviewed all content, verified the citations, and validated the clinical conclusions presented in this document.

The analysis of nephrotoxicity mechanisms, assessment of risk factors and prevention strategies, and clinical recommendations reflect my professional judgment and expertise. The confidence matrix evaluation of references also represents my critical appraisal of the evidence quality.

This document should be considered a clinician-reviewed literature synthesis that leveraged AI as a research tool while maintaining appropriate clinical oversight and professional responsibility for all conclusions.

Date of generation: May 11, 2025

Educational Resources

  • [[well water contamination, diarrhea and aki|Student Guide: Well Water Contamination, Diarrhea And Aki]] — PA/medical student educational guide
  • [[appendix_e_pain_management_deep_dive|Student Guide: Appendix E Pain Management Deep Dive]] — PA/medical student educational guide
  • [[drug-induced-aki-student-handout|Student Handout: Drug Induced Aki]] — PA/medical student educational guide